BioSpace News Archive

- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that they are bringing an increased awareness of advanced oral healthcare through the use of dental lasers to those in the Dallas-Fort Worth area.

Axcella Health, a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Svetlana Marukian, Ph.D., Senior Director, Discovery, will present new data from Axcella’s AXA1125 liver program at the Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium,

Liht Cannabis Corp. (CSE: LIHT) (OTCQX: LIHTF) (FSE: 2M0) (“Liht”) or the “Company”) appoints a fifth board member and updates its shareholders on the outcome of its Annual Special General Meeting (“ASGM”) held on December 17th, 2018 in Kelowna, British Columbia.

Meridian is donating $100,000 worth of coats, hats, gloves, and socks to the homeless through local shelters

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces today that the Company has delivered notice of termination to FSD Pharma Inc. (“FSD”) under the previously announced binding letter of intent dated October 22, 2018 (the “LOI”) for the acquisition of the Company by FSD (the “Transaction”).

Nuvo Pharmaceuticals Inc. announced that its wholly owned subsidiary, Nuvo Pharmaceuticals DAC has entered into a license and supply agreement with Heumann Pharma GmbH & Co. Generica KG for the exclusive right to distribute, market and sell Resultz® in Germany

In the hustle and bustle of holiday shopping and with 2019 fast approaching, For Eyes is here to make sure Americans don’t miss another important deadline.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will receive $619,546, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).

Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced today that the company applauds the United States Congress for the passage of The Agricultural Improvement Act of 2018, also known as the 2018 Farm Bill, that includes Senate Majority Leader Mitch McConnell’s Hemp Farming Act of 2018.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).